What is Opus Genetics?
Opus Genetics operates at the intersection of biotechnology and ophthalmology, focusing on the development of durable, vision-preserving gene therapies. The company is dedicated to correcting genetic defects that lead to retinal degeneration, a field characterized by high barriers to entry and significant therapeutic potential. Headquartered in the United States, the firm translates complex scientific breakthroughs into clinical-grade solutions for both rare and common retinal disorders. By maintaining a rigorous focus on translational medicine, Opus Genetics has established itself as a key player in the global effort to restore vision through molecular intervention. Its market position is defined by a commitment to safety, efficacy, and the long-term commercialization of transformative ophthalmic treatments.
How much funding has Opus Genetics raised?
Opus Genetics has raised a total of $164.4M across 2 funding rounds:
Angel/Seed
$4.5M
Stock/Share Issuance
$159.9M
Angel/Seed (2023): $4.5M with participation from North Carolina Biotechnology Center
Stock/Share Issuance (2026): $159.9M led by Oberland Capital
Key Investors in Opus Genetics
North Carolina Biotechnology Center
NCBiotech is a prominent life science economic development organization that facilitates the transition of research into marketable products through strategic resource allocation and industry networking.
Oberland Capital
Oberland Capital is a specialized private investment firm that provides flexible financing solutions, including royalty monetization, to accelerate the commercialization of healthcare innovations.
What's next for Opus Genetics?
With the recent capital secured, Opus Genetics is expected to prioritize the expansion of its clinical trial infrastructure and the scaling of its manufacturing capabilities. The strategic roadmap likely involves moving lead candidates through advanced clinical phases while exploring potential partnerships to broaden its therapeutic reach. As the company transitions into a more mature phase of its lifecycle, the focus will shift toward regulatory milestones and the eventual commercialization of its gene therapy portfolio. Investors and industry stakeholders will be monitoring the firm's ability to maintain its competitive edge in the rapidly evolving landscape of genetic medicine, particularly as it seeks to solidify its leadership in the treatment of inherited retinal conditions.
See full Opus Genetics company page
